VERA THERAPEUTICS INC (VERA) Fundamental Analysis & Valuation

NASDAQ:VERA • US92337R1014

39.3 USD
-1.12 (-2.77%)
At close: Mar 3, 2026
39.5 USD
+0.2 (+0.51%)
Pre-Market: 3/4/2026, 5:11:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VERA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall VERA gets a fundamental rating of 2 out of 10. We evaluated VERA against 520 industry peers in the Biotechnology industry. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability. VERA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. VERA Profitability Analysis

1.1 Basic Checks

  • VERA had negative earnings in the past year.
  • In the past year VERA has reported a negative cash flow from operations.
  • In the past 5 years VERA always reported negative net income.
  • In the past 5 years VERA always reported negative operating cash flow.
VERA Yearly Net Income VS EBIT VS OCF VS FCFVERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -40.78%, VERA is in line with its industry, outperforming 57.88% of the companies in the same industry.
  • The Return On Equity of VERA (-49.56%) is better than 65.58% of its industry peers.
Industry RankSector Rank
ROA -40.78%
ROE -49.56%
ROIC N/A
ROA(3y)-39.55%
ROA(5y)-45.08%
ROE(3y)-56.77%
ROE(5y)-66.6%
ROIC(3y)N/A
ROIC(5y)N/A
VERA Yearly ROA, ROE, ROICVERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERA Yearly Profit, Operating, Gross MarginsVERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. VERA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for VERA has been increased compared to 1 year ago.
  • VERA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, VERA has a worse debt to assets ratio.
VERA Yearly Shares OutstandingVERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
VERA Yearly Total Debt VS Total AssetsVERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • VERA has an Altman-Z score of 11.16. This indicates that VERA is financially healthy and has little risk of bankruptcy at the moment.
  • VERA has a Altman-Z score of 11.16. This is amongst the best in the industry. VERA outperforms 83.08% of its industry peers.
  • A Debt/Equity ratio of 0.12 indicates that VERA is not too dependend on debt financing.
  • VERA has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: VERA underperforms 63.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 11.16
ROIC/WACCN/A
WACCN/A
VERA Yearly LT Debt VS Equity VS FCFVERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 13.64 indicates that VERA has no problem at all paying its short term obligations.
  • VERA's Current ratio of 13.64 is amongst the best of the industry. VERA outperforms 89.62% of its industry peers.
  • A Quick Ratio of 13.64 indicates that VERA has no problem at all paying its short term obligations.
  • VERA's Quick ratio of 13.64 is amongst the best of the industry. VERA outperforms 89.62% of its industry peers.
Industry RankSector Rank
Current Ratio 13.64
Quick Ratio 13.64
VERA Yearly Current Assets VS Current LiabilitesVERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VERA Growth Analysis

3.1 Past

  • VERA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.45%.
EPS 1Y (TTM)-69.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VERA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.94% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.24%
EPS Next 2Y13.73%
EPS Next 3Y25.99%
EPS Next 5Y30.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERA Yearly Revenue VS EstimatesVERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
VERA Yearly EPS VS EstimatesVERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. VERA Valuation Analysis

4.1 Price/Earnings Ratio

  • VERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERA Price Earnings VS Forward Price EarningsVERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERA Per share dataVERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • VERA's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.73%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VERA Dividend Analysis

5.1 Amount

  • No dividends for VERA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERA Fundamentals: All Metrics, Ratios and Statistics

VERA THERAPEUTICS INC

NASDAQ:VERA (3/3/2026, 8:00:02 PM)

Premarket: 39.5 +0.2 (+0.51%)

39.3

-1.12 (-2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners103.41%
Inst Owner Change12.81%
Ins Owners0.95%
Ins Owner Change2.16%
Market Cap2.80B
Revenue(TTM)N/A
Net Income(TTM)-299.62M
Analysts83
Price Target76.26 (94.05%)
Short Float %11.47%
Short Ratio7.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.54%
Min EPS beat(2)-8.76%
Max EPS beat(2)-6.33%
EPS beat(4)0
Avg EPS beat(4)-16.58%
Min EPS beat(4)-43.18%
Max EPS beat(4)-6.33%
EPS beat(8)1
Avg EPS beat(8)-11.18%
EPS beat(12)3
Avg EPS beat(12)-6.91%
EPS beat(16)4
Avg EPS beat(16)-7.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.21%
PT rev (3m)19.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.64
P/tB 4.64
EV/EBITDA N/A
EPS(TTM)-4.66
EYN/A
EPS(NY)-4.76
Fwd EYN/A
FCF(TTM)-3.39
FCFYN/A
OCF(TTM)-3.38
OCFYN/A
SpS0
BVpS8.47
TBVpS8.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.78%
ROE -49.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.55%
ROA(5y)-45.08%
ROE(3y)-56.77%
ROE(5y)-66.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.64
Quick Ratio 13.64
Altman-Z 11.16
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.06%
EPS Next Y-2.24%
EPS Next 2Y13.73%
EPS Next 3Y25.99%
EPS Next 5Y30.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-88.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-78.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.02%
OCF growth 3YN/A
OCF growth 5YN/A

VERA THERAPEUTICS INC / VERA FAQ

What is the ChartMill fundamental rating of VERA THERAPEUTICS INC (VERA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VERA.


Can you provide the valuation status for VERA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to VERA THERAPEUTICS INC (VERA). This can be considered as Overvalued.


How profitable is VERA THERAPEUTICS INC (VERA) stock?

VERA THERAPEUTICS INC (VERA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for VERA stock?

The Earnings per Share (EPS) of VERA THERAPEUTICS INC (VERA) is expected to decline by -2.24% in the next year.